Clinical Trial

A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of oral doses of FB418 in healthy adult subjects and healthy elderly subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-13.
Status change: Not Yet Recruiting → Recruiting 2024-11-27
Trial Details
NCT Number NCT05995782
Lead Sponsor 1ST Biotherapeutics, Inc.
Conditions Parkinson Disease Psychosis, Amyotrophic Lateral Sclerosis (ALS)
Enrollment 64 participants
Start Date 2023-12-20
Primary Completion 2024-12 (estimated)
Study Completion 2024-12 (estimated)
Updated on ClinicalTrials.gov 2024-12-02